Genetic Trial to Study Diarrhea in Patients With Stage III Colon Cancer Who Are Receiving Chemotherapy

Plain-language summary

This study examined the genetic causes of diarrhea in patients with stage III colon cancer who were receiving chemotherapy. Patients aged 18 and over with histologically confirmed stage III colon cancer enrolled in the CALGB-89803 trial could take part. It was carried out as a study with no assigned phase and has been completed.

The summary above is a plain-language rendering of the official record. The original English title is shown for reference.

Trial details

Phase

N/A

Status

Completed

Sponsor

Alliance for Clinical Trials in Oncology

Intervention

mutation analysis, polymorphic microsatellite marker analysis

Start date

4/1/2002

Estimated completion

11/1/2006

Countries

United States, Canada, Puerto Rico

Related genes

Locations

• Anniston, United States
• La Jolla, United States
• Los Angeles, United States
• San Diego, United States
• San Francisco, United States
• San Francisco, United States
• Newark, United States
• Washington D.C., United States
• Washington D.C., United States
• Washington D.C., United States
• Fort Lauderdale, United States
• Hollywood, United States
• Miami Beach, United States
• Orlando, United States
• West Palm Beach, United States
• Chicago, United States
• Chicago, United States
• Chicago, United States
• Chicago, United States
• River Forest, United States
• Rockford, United States
• Fort Wayne, United States
• South Bend, United States
• Iowa City, United States
• Louisville, United States
• Baltimore, United States
• Baltimore, United States
• Boston, United States
• Worcester, United States
• Saint Joseph, United States
• Minneapolis, United States
• Minneapolis, United States
• Columbia, United States
• Columbia, United States
• St Louis, United States
• St Louis, United States
• St Louis, United States
• Omaha, United States
• Las Vegas, United States
• Las Vegas, United States

+44

Eligibility criteria

Criteria are reproduced from the ClinicalTrials.gov record in the original English. Only the trial team can determine eligibility.

DISEASE CHARACTERISTICS:

* Histologically confirmed stage III adenocarcinoma of the colon
* Enrolled on CALGB-89803 and must fall into 1 of the following categories:

  * Received irinotecan, fluorouracil, and leucovorin calcium and experienced at least 1 of the following:

    * Grade 3-4 diarrhea
    * Grade 4 neutropenia
    * Grade 1 or lower diarrhea AND grade 2 or lower neutropenia
  * Received fluorouracil and leucovorin calcium and experienced at least 1 of the following:

    * Grade 3-4 diarrhea
    * Grade 1 or lower diarrhea AND grade 2 or lower neutropenia

PATIENT CHARACTERISTICS:

Age

* 18 and over